Background: Long-term results comparing percutaneous transluminal angioplasty with or without stenting (PTA/S) and open surgical bypass for chronic limb-threatening ischemia (CLTI) in patients who have had no prior intervention are lacking.
There are currently two treatments available for patients with chronic limb-threatening ischemia (CLTI): open surgical bypass and percutaneous transluminal angioplasty with or without stenting (PTA/S). Although promoted for its long-term anatomic patency and clinical durability, bypass has also been shown to escalate morbidity and to increase resource use. [1] [2] [3] [4] Support for balloon angioplasty, on the other hand, highlights the benefits of lower procedural morbidity and mortality, faster procedural times, and reduced hospital stay. 5 Proponents of PTA/S additionally claim that failed angioplasty does not threaten successive surgery and preserves collaterals; however, recent data have not only suggested otherwise but have also illustrated higher rates of restenosis. [6] [7] [8] [9] Previous studies have attempted to compare bypass and PTA/S for various degrees of lower extremity limb ischemia with varying methodologic problems. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Published in 2005, the randomized Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL) trial attempted to offer answers to similar concerns, concluding no difference between bypass-first and angioplasty-first strategies up to 2 years, after which overall survival and amputation-free survival were better after bypass. 21 The BASIL trial has been criticized, however, for its strict eligibility requirements and for its low number of patients with infrapopliteal disease. Furthermore, patients within their cohort included those with a prior intervention and subsequent clinical failure, limiting the study's ability to make recommendations for patients undergoing a first-time revascularization.
Conflicting evidence continues to amplify controversy about which treatment, if any, is associated with a better clinical outcome and is a more effective use of health care resources in patients potentially suitable for both treatments with legs threatened by CLTI. With the increasing proficiency of endovascular techniques, the incidence of PTA/S as a first-line therapy for CLTI has similarly increased. With varying success rates reported throughout the literature, however, it remains to be determined whether endovascular techniques have better long-term limb salvage rates compared with open surgical bypass. Because of the inconclusive information about first-time lower extremity interventions for CLTI, we sought to describe our institution's long-term experience with both endovascular and bypass repair in hopes of finding a statistically preferred treatment to minimize reintervention, stenosis, amputation, and mortality after any first-time lower extremity revascularization for CLTI.
METHODS
We performed a retrospective review of all patients with CLTI undergoing a first-time lower extremity intervention by the Division of Vascular and Endovascular Surgery at Beth Israel Deaconess Medical Center. We individually reviewed the medical records of all open surgical bypass and all PTA/S interventions from January 2005 to October 2014. Patients who received previous interventions on the ipsilateral limb (whether at the Division of Vascular and Endovascular Surgery at Beth Israel Deaconess Medical Center or at an outside institution) or interventions involving the iliac arteries and above were excluded. Patients undergoing a concomitant procedure, including endarterectomy, profundaplasty, thrombectomy, atherectomy, or patch, were included and adjusted for in our analysis. Primary outcomes included 30-day mortality, wound healing, restenosis (>3.5Â step-up by duplex ultrasound), primary patency, reintervention, major amputation, RAS events (a composite variable denoted by reintervention, major amputation, or stenosis), and mortality. Demographics, discharge medications, comorbidities, and perioperative complications were also recorded. The decision of intervention type was surgeon dependent and varied over time with the acquisition of endovascular skills. In general, primary angioplasty with selective stenting was done according to the clinical judgment of the attending physician at the time of the procedure. Routine statin use was introduced over time. PTA/S patients were generally treated with clopidogrel for 1 month postoperatively and aspirin indefinitely. Technical success after PTA/S was defined as <30% residual stenosis and no flow-limiting dissection. Technical success after a bypass procedure was defined as a patent graft at completion of the procedure and no significant defect in the vein on angioscopy and continuous-wave Doppler interrogation.
Typical follow-up interval was every 3 to 4 months for 2 years and every 6 months thereafter, with the modality being arterial duplex ultrasound imaging and anklebrachial indices (ABIs) with forefoot pulse volume recordings (PVRs) or toe pressures. Before 2008, only PVR and ABI information was recorded; after 2008, to obtain more quantitative analyses of flow to the forefoot, most surgeons routinely recorded toe pressures. Criteria for restenosis >75% was a >3.5-fold increase in peak systolic velocity by duplex ultrasound or angiographic measurement. Intervention was performed for symptomatic graft restenosis and threatened asymptomatic grafts (peak systolic velocity ratio >3.5 to 4 or low graft velocities <30 cm/s). In general, patients did not undergo reinterventions for an asymptomatic restenosis after PTA/S alone; however, we were more likely to reintervene with PTA/S for an asymptomatic in-stent restenosis with peak systolic velocity ratio of >3.5 to 4. We were less likely to reintervene percutaneously for a symptomatic restenosis if the disease was extensive and restenosis was rapid as we believe that this has a low likelihood of deriving a durable benefit. Symptom recurrence and disease progression were determined by the attending surgeon at follow-up. We included patients whose disease severity was distinctly identifiable as CLTI and who underwent either an angioplasty with or without stenting or an open surgical bypass. Indications for intervention included tissue loss (ie, gangrene or ulcer) and rest pain. Limbs presenting with more than one indication were assigned as having only the most severe symptom; gangrene was considered most severe, ulcer moderately severe, and rest pain least severe. Femoropopliteal lesion anatomy and severity were defined according to the modified TransAtlantic
Inter-Society Consensus (TASC II) 
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RESULTS
Characteristics of the patients. Of the 2869 total lower extremity revascularizations performed between January 2005 and October 2014, there were 1533 procedures excluded from the analysis: 663 interventions performed on limbs with noncritical limb ischemia symptoms, 437 reinterventions, and 433 limbs that had undergone a previous intervention. Ultimately, 1336 met our inclusion criteria (ie, a first-time lower extremity intervention for CLTI): 668 undergoing a first-time bypass procedure and 668 undergoing a first-time PTA/S procedure. The proportional distribution of procedure type during our decade-long study progressed from bypass in more than three-quarters of the yearly CLTI revascularizations to a more even distribution, with angioplasty slowly becoming the more common practice (Fig 1) . Bypassfirst patients, as compared to PTA/S-first patients, were younger (71 vs 72 years; P ¼ .02), more often male (62% vs 56%; P ¼ .02), and more often white (82% vs 74%; P < .001; Table I ). Bypass-first patients more commonly smoked (both current and prior history; 26% vs 16% [P < .001] and 68% vs 53% [P < .001], respectively) and suffered from chronic obstructive pulmonary disease (COPD; 14% vs 10%; P ¼ .01), whereas bypass-first patients less commonly suffered from dialysis dependence (17% vs 23%; P ¼ .01) and hypertension (82% vs 89%; P < .001). Although patients presenting with gangrene were statistically similar between groups (30% vs 27%; P ¼ .36), ulcerations in the bypass-first cohort were significantly less common (48% vs 57%; P ¼ .001), while rest pain was more common (23% vs 16%; P ¼ .001). Discharge medications differed between procedure types as well: bypass-first patients were less often prescribed aspirin (82% vs 86%; P ¼ .046), clopidogrel (30% vs 84%; P < .001), any antiplatelet (86% vs 97%; P < .001), and dual antiplatelets (25% vs 68%; P < .001) and were more commonly prescribed statins (81% vs 75%; P < .01).
Finally, bypass-first interventions were performed significantly more often in patients with both preoperative femoropopliteal TASC D lesions (31% vs 13%; P < .001) and preoperative tibial TASC D lesions (37% vs 27%; P < .001).
In bypass-first patients, the distal targets were primarily infrapopliteal (44% in the tibial and peroneal arteries and 25% in the inframalleolar dorsalis pedis, posterior tibial, plantar, or tarsal arteries), and single-segment great saphenous vein conduits were used in more than three-quarters of procedures (77% ; Table II ). Nonreversed great saphenous vein was the most common conduit (41%), and any single-segment vein conduit was used in 82% of the first-time bypass procedures. Twelve percent of bypass-first procedures used composite vein and 6% used prosthetic material. Of the 668 first-time PTA/S procedures, the most common distal lesions treated were in the tibial and peroneal arteries (55%). Furthermore, approximately 44% of all PTA/S-first were multilevel. Of all PTA/S-first procedures, the superficial femoral artery was intervened on the most (63%), 27% of which included a stent (Fig 2) . Approximately 38% of all PTA/S-first procedures included stenting. The median follow-up was 18 months for bypass (range, <1-114) and 14 months for PTA/S (range, <1-118).
Perioperative outcomes. Perioperative mortality did not differ between procedure types, occurring in 22 bypass-first (3.3%) and 19 PTA/S-first patients (2.8%; P ¼ .63). There was a higher overall complication rate after a bypass, primarily due to surgical site infections (10% ; Table III) . Bypass-first patients had a significantly longer total mean hospital length of stay (LOS; 10 vs 7 days; P < .001), mean preoperative LOS (4 vs 3 days; P < .01), and mean postoperative LOS (7 vs 5 days; P < .001). In addition, within 30 days of the index procedure, bypass-first patients underwent partial foot or toe amputations less often than PTA/S-first patients did (9% vs 14%; P < .01). Although lower among bypass-first patients, 30-day transmetatarsal amputations (4% vs 5%; P ¼ .60) and wound débridement (8% vs 9%; P ¼ .40) did not differ between procedure types.
Long-term outcomes. Complete wound healing at 6-month follow-up was significantly better after an initial bypass compared to an initial PTA/S (43% vs 36%; P < .01). On survival analysis, bypass patients had a higher freedom from restenosis compared to PTA/S patients (61% vs 45% at 3 years; P < .001; Fig 3) . After adjusting for baseline characteristics (ie, age, gender, race, procedure year, hypertension, indication for intervention, concomitant procedures, diabetes, dialysis dependence, COPD, congestive heart failure [CHF], history of smoking, femoropopliteal TASC class, tibial TASC class, and discharge medications), multivariable predictors of restenosis for all patients included a first-time PTA/S intervention (hazard ratio, 1.7; 95% confidence interval, 1. Bypass-first patients less commonly underwent any partial foot or toe amputations (23% vs 30%; P < .01). In further stratifying by indication for intervention, partial foot or toe amputations did not differ between bypassfirst and PTA/S-first rest pain patients (9.2% vs 9.5%; P ¼ .93) or ulcer patients (19% vs 25%; P ¼ .08); however, there was a significantly lower proportion of bypass-first patients with gangrene undergoing any form of minor amputation (38% vs 53%; P < .01). Freedom from major amputation did not differ between bypass and PTA/S groups either during 6 months (93% vs 92%, respectively; P ¼ .88) or throughout follow-up (81% vs 85% at 3 years; P ¼ .40; Fig 5) . Among bypass-first patients, major amputation was predicted by gangrene as the indication for intervention (4. 
-2.2], respectively).
Freedom from a RAS event within 3 years was 47% in bypass-first patients and 34% in PTA/S-first patients (P < .001; Fig 6) . Finally, survival was higher in the bypass-first patients (61% vs 52% at 3 years; P < .01; Fig 7) , where all patient mortality was predicted by age (1. Table IV ). An endovascular reintervention was the most common procedure in both groups, yet it occurred more often in PTA/S-first patients (22% vs 39%; P < .001). Conversely, bypass reinterventions did not differ between bypass-first and PTA/S-first patients (21% vs 16%; P ¼ .18). Overall, approximately half of the PTA/S patients underwent a reintervention because of recurring or nonhealing ulcers (48% vs 34% in bypass patients; P < .01), whereas significantly more patients with a first-time bypass procedure underwent a reintervention on an asymptomatic duplex ultrasounddetected stenosis (22% vs 9%; P < .001).
Sensitivity analyses. To control for potential study and cohort limitations, we performed several sensitivity analyses aimed at mitigating any potential confounding effects. As previously mentioned and illustrated in Fig 1, procedure type varied over time as the acquisition of endovascular skills improved; to account for these potential technical improvements, we constructed a separate analysis with the same primary outcomes limited to the years in which PTA/S was the more common procedure type (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Restriction of the analysis to these years did not yield any substantial differences in wound healing, restenosis, primary patency, reintervention, major amputation, RAS events, or survival between bypass-first and PTA/S-first interventions for CLTI. Furthermore, as ulcerations were significantly less common in the bypass-first cohort, we performed additional (and separate) sensitivity analyses stratifying our multivariable models by ulcer-only patients and tissue loss-only patients, which also did not appreciably alter any primary outcomes. Finally, as PTA/S-first patients were more commonly dependent on dialysis, we performed a final sensitivity analysis in which patients on dialysis (n ¼ 263) were removed. Removal of these patients did alter the unadjusted and adjusted rates of death, both shown to no longer depict a significant difference between bypass-first and PTA/S-first patients (P ¼ .25 and P ¼ .20, respectively). In addition, after the removal of these patients, the unadjusted 6-month wound healing rates were shown to no longer be statistically different between groups (P ¼ .09); in adjusting for baseline characteristics, however, the 6-month wound healing rates remain significantly improved after bypassfirst interventions (P < .01).
DISCUSSION
Our data show that in patients undergoing a first-time lower extremity intervention for CLTI, bypass-first patients had significantly improved wound healing, greater freedom from restenosis and reintervention, higher primary patency rates, and lower mortality than those who underwent a first-time PTA/S. Importantly, in our experience, reinterventions in PTA/S-first patients were more commonly performed on ongoing wound problems, whereas reinterventions on bypass patients occurred more commonly for asymptomatic duplex ultrasound-detected lesions. Although a bypass-first approach was associated with a significantly greater total, preoperative, and postoperative length of hospital stay as well as with more perioperative complications (primarily due to surgical site infections), perioperative mortality did not differ between procedure types, and long-term mortality was significantly less frequent after an index bypass. Furthermore, as expected, limb salvage did not differ between procedure types. Importantly, preoperative femoropopliteal TASC D lesions proved predictive for major amputation among all patients, whereas femoropopliteal TASC D and tibial TASC C and TASC D lesions proved predictive of major amputation in bypass-first patients. Finally, among bypass-first patients, vein conduits proved most effective in decreasing major amputation rates. Overall, these data illustrate that compared with a first-time PTA/S procedure, a bypassfirst procedure provides a more durable and long-term repair with a significantly higher freedom from restenosis, significantly higher freedom from reintervention, better wound healing, and greater survival.
Previously, the randomized BASIL trial concluded that bypass surgery-first and balloon angioplasty-first strategies provided equal outcomes for amputation-free survival up to 2 years, after which overall survival and amputation-free survival were better after bypass. 21 Furthermore, this study found that reintervention increased in patients receiving bypass as a secondary treatment (which occurred mostly in patients receiving PTA/S as a primary treatment). The BASIL trial has been criticized, however, for its strict eligibility requirements, potentially affecting its real-world generalizability, and for its low number of patients with infrapopliteal disease. Furthermore, the BASIL trial cohort included patients with a clinical failure after prior interventions and did not consist of exclusively first-time interventions; however, both our results and the BASIL trial findings raise the possibility that patients can benefit from a bypass-first strategy as opposed to an angioplasty-first strategy. Overall, our data suggest that the BASIL trial results may be more generalizable than previously assumed. A 2013 study conducted by Jones et al evaluated the adverse effects of subsequent revascularizations after infrainguinal treatment failure in patients suffering from peripheral arterial disease. 24 After comparison of 2350 patients undergoing a primary infrainguinal bypass with 1154 patients undergoing secondary infrainguinal bypass (after a failed PTA/S or bypass), secondary bypass patients were shown to have inferior 1-year outcomes, including major adverse limb event-free survival and reintervention-or amputation-free survival, regardless of the prior failed treatment type (PTA/S or bypass). Similar to our data, Jones et al advocated appropriate selection of patients rather than an "endovascular first" approach, an important finding as recent studies have shown that distal targets can be altered from multiple percutaneous interventions. 8, 9 Finally, a study conducted by Engelhardt et al evaluated the initial treatment of 104 patients presenting with a first episode of CLTI to determine their amputation-free survival rate. 25 In total, 65% received some form of revascularization: surgical arterial reconstruction in 55% and PTA/S in 45%. Twenty-two percent of limbs were initially treated nonoperatively, and 4.3% died before conservative therapy could be initiated. In total, after the initial revascularization treatment, six limbs (22%) required further interventions for ongoing CLTI, including surgical reconstructions and secondary amputations. With a 3-year limb salvage rate of 73%, patient survival rate of 41%, and amputation-free survival rate of 31%, Engelhardt et al concluded that two-thirds of all patients presenting with a first episode of CLTI should be considered for some form of direct revascularization. However, although the study suggested that many patients ill-qualified for bypass procedures may be instead offered endovascular options for revascularization, to date, no reliable formula to successfully identify such factors for selection of patients exists.
Like the BASIL trial, this study illustrates the importance of selection of patients, especially in regard to cardiac risk and burden of disease. Although there were few significant differences in many comorbidities that constitute cardiac risk, dialysis dependencedan important cardiac risk factor that has been shown to increase myocardial infarction and death after revascularizationdwas shown to be higher among the PTA/S-first patients, illustrating that there may be additional increases in cardiac risk within the PTA/S patients not presently captured within this analysis. [26] [27] [28] In addition, although uncategorized within this population of patients, poor surgical candidatesdshown to have higher rates of 30-day mortality, loss of patency, limb loss, and long-term mortalitydare another important subset of patients highlighting one of the many challenges involved in treating CLTI. 29 Although prior studies have seen an increase in 30-day and perioperative mortality among bypass patients, we saw similar rates between the two groups, truly emphasizing the burden of disease that PTA/S patients have. Importantly, our study illustrates the increased risk for major amputation, RAS events, and reintervention among limbs with femoropopliteal TASC C and TASC D lesions; however, we believe that there are several additionally important factors that should play a role in selection of revascularization strategy. For example, as discussed in our previous work on the Wound, Ischemia, and foot Infection (WIfI) classification system, the extent of the foot disease and the severity of the wound play critical roles in understanding a patient's risk of undergoing a future event. 30 In addition, medical condition of patients and availability of adequate conduit are necessary factors in deciding on bypass vs PTA/S. In our practice, a relatively healthy patient with a good conduit, extensive tissue loss, and severe occlusive disease would typically dictate a bypass; however, it is hoped that our enrollment of patients in the BEST trial will better elucidate answers that this retrospective analysis cannot. Ultimately, based on our study and others such as the BASIL trial, sites not enrolling in the BEST trial might strongly consider bypass in limbs with TASC C and D lesions. Notably, however, we now use drug-coated balloons and drug-eluting stents in the femoropopliteal vessels, which we expect to improve PTA/S outcomes, even among the more demanding TASC C and TASC D lesions.
There are important limitations to this study. First, it was a retrospective, single-center review in which patients were allocated to treatment on the basis of the surgeon's preference, which has changed over time. Second, as a retrospective study, there are many patient detailsdsuch as vein mapping information within the PTA/s-first patientsdthat are unreliably documented throughout the study period and may theoretically limit the conclusions that can be drawn. Before 2008, our institution routinely recorded PVRs and ABIs; however, PVRs are not quantitative measures, and as three-quarters of the patients within our study have diabetes, there is a predisposition for a number of limbs to have calcified tibial vessels and therefore to have unreliable ABI information. After 2008, most surgeons within our institution began using toe pressures routinely; unfortunately, it is difficult to quantitatively compare patients in this regard when forefoot PVR, ABI, and toe pressure information is unobtainable in the high number of patients with toe lesions or missing toes. Ultimately, the various difficulties of recording valuable and dependable duplex ultrasound surveillance on all patients throughout the study period caused a comparative shortcoming that is not uncommon in previous studies; it is hoped that future studies can provide more thorough information in this regard. Furthermore, our data set does not contain cost-related data and therefore does not help resolve the unmet need to better understand how the high vascular readmission and revascularization rates for peripheral arterial disease fit into the discussion of cost-effectiveness and cost saving. Finally, these data include only revascularization attempts and do not reflect outcomes for those patients treated with primary amputation or medical management as a contrast. Regardless, this study remains one of the largest reported analyses of initial treatment of CLTI comparing surgical bypass and PTA/S.
CONCLUSIONS
These data support the conclusions of the BASIL trial and suggest that on the basis of the reduced mortality, improved wound healing, and fewer future interventions, for appropriately selected patients, bypass may be preferred in the midterm and long term. Therefore, in relatively fit patients expected to live >2 years, the apparent improved durability and reduced reintervention rate of open surgical bypass could outweigh the short-term considerations of increased morbidity, especially in those with an available and suitable singlesegment great saphenous vein conduit. Conversely, regardless of the high failure and reintervention rate associated with PTA/S, patients who are expected to live for fewer than 1 or 2 years and have significant comorbidities may be better suited, when possible, for a PTA/S-first approach. As such, irrespective of the methodologic differences between our study and the BASIL trial, the results of the latter may be more generalizable to the larger populations than initially expected. Ultimately, we hope that future studies focus on the comparison of first-time interventions for patients who are medically fit for bypass and have adequate singlesegment great saphenous vein as we believe that further subgroup evaluation may better elucidate which procedure type best suits particular patients. 
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